摘要
目的坦洛新联合黛力新治疗慢性非细菌性前列腺炎伴抑郁症的临床疗效及对患者免疫指标、情绪及生活质量的影响.方法将60例慢性非细菌性前列腺炎伴抑郁症患者按随机数字表法分为两组,每组30例.两组均予以坦洛新治疗,观察组在此基础上联合黛力新治疗,观察8周.比较两组的临床疗效,于治疗前后检测免疫相关指标,并采用美国国立卫生研究院慢性前列腺炎症状指数、焦虑自评量表及简明健康状况调查表评定前列腺炎临床症状、焦虑情绪及生活质量.结果(1)观察组总有效率显著高于对照组(P<0.05).(2)治疗后两组美国国立卫生研究院慢性前列腺炎症状指数及焦虑自评量表评分较治疗前显著降低(P<0.05),简明健康状况调查表评分较治疗前显著升高(P<0.05),两组比较差异有统计学意义(P<0.05).(3)治疗后两组白细胞计数、C反应蛋白、肿瘤坏死因子-γ、白细胞介素-1β、白细胞介素-2水平均较治疗前显著降低(P<0.05),观察组显著低于对照组(P<0.05).结论坦洛新联合黛力新治疗慢性非细菌性前列腺炎伴抑郁症疗效显著,可明显改善患者免疫相关指标,缓解患者的焦虑情绪,提高其生活质量.
Objective To explore the clinical efficacy of tamsulosin combined with deanxit in the treatment of chronic nonbacterial prostatitis with depression and its effect on patients'immune indicators,mood and quality of life.Methods 60 cases of patients with chronic nonbacterial prostatitis with depression were randomly divided into two groups,30 cases each.The control group was treated by tamsulosin,the observation group was treated by deanxit and tamsulosin for 8 weeks.Compare the clinical efficacy of the two groups,and detect immune-related indicators before and after treatment.NIH-CPSI,SAS and SF-36 were used to evaluate the clinical symptoms,anxiety and quality of life of prostatitis.Results(1)The total effective rate of the observation group was higher than the control group(P<0.05).(2)After treatment,the NIH-CPSI and SAS scores were significantly lower than before treatment(P<0.05),and the SF-36 score was significantly higher than before treatment(P<0.05).There was a statistically significant difference between the two groups(P<0.05).(3)After treatment,the levels of WBC,CRP,TNF-γ,IL-1β,and IL-2 were significantly lower in the two groups than before treatment(P<0.05),and the observation group was significantly lower than the control group(P<0.05).Conclusions Tamsulosin combined with deanxit have significant effect on chronic nonbacterial prostatitis with depression,which can significantly improve patients'immune-related indicators,relieve patients'anxiety and improve quality of life.
作者
郑会忠
郑航
郭宏
王行皓
张会清
Zheng Huizhong;Zheng Hang;Guo Hong;Wang Xinghao;Zhang Huiqing(Rongjun Hospital of Henan Province,Xinxiang 453002,Henan,China)
出处
《临床心身疾病杂志》
CAS
2020年第3期27-29,59,共4页
Journal of Clinical Psychosomatic Diseases
基金
新乡医学院第一附属医院心脏中心求实探索基金资助项目(编号XZZX2017004)。
